Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126
Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026
Azitra, Inc. Announces Reverse Stock Split
Azitra Enters Sales Agreement With A.G.P. For Common Stock Offering; May Offer Common Stock Up To $3.50M Through A.G.P.
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Azitra Regains NYSE American Compliance
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Anitra Q2 EPS $(0.17) Misses $(0.12) Estimate
Azitra Reports Results From Two Ex Vivo Human Skin Tissue Studies Evaluating Distribution And Anti-Wrinkle Activity Of Filaggrin Domain Supernatant
/C O R R E C T I O N -- Azitra, Inc./
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
Azitra Announce Ex Vivo Results From Two Human Skin Tissue Studies Evaluating Anti-Wrinkle Activity In Filaggrin Domain Containing Supernatant
Why Did Azitra (AZTR) Stock Jump Over 25% After Hours?
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Azitra To Pause Further Enrollment In ATR-12 Trial To Redirect Funds To ATR-COSF
Azitra, Inc. to Present at 2026 BIO International Convention
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.